NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 1-5, 2026



ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access



https://doi.org/10.59298/NIJSES/2026/72.152026

# From Adipose Dysfunction to Glycemic Control: The Transformative Role of Nanotechnology in Obesity and Diabetes

**Muhindo Anitah**

**Department of Pharmacy Kampala International University Uganda**
**Email: anitah.muhindo@studwc.kiu.ac.ug**

## ABSTRACT

Obesity and type 2 diabetes (T2D) are two of the most pressing global health concerns, often coexisting as part of a complex metabolic syndrome. At the heart of both conditions is adipose dysfunction, which contributes to insulin resistance, disturbed lipid metabolism, and impaired glucose control. While traditional therapeutic strategies focus on symptom management, they often fail to target the underlying causes of adipose dysfunction and glycemic dysregulation. Nanotechnology has emerged as a promising solution, offering the ability to precisely address the molecular mechanisms involved in obesity and diabetes through targeted drug delivery, modulation of inflammatory pathways, and restoration of insulin sensitivity. By leveraging the unique properties of nanoparticles, nanocarriers can be designed to specifically target adipose tissue, liver, muscle, and pancreas which are key organs involved in glucose metabolism and insulin resistance. This review examines the transformative role of nanotechnology in managing adipose dysfunction and glycemic control, focusing on its potential to modulate lipid metabolism, improve insulin sensitivity, and enhance therapeutic outcomes in obesity-related metabolic diseases. The article also discusses the challenges in translating nanomedicine from the laboratory to clinical practice and highlights the translational opportunities for nanotechnology in treating obesity and diabetes.

**Keywords**: Nanotechnology, Obesity, Diabetes, Adipose Dysfunction, Glycemic Control, Insulin Resistance.

## INTRODUCTION

Obesity and type 2 diabetes (T2D) are interconnected diseases that have reached epidemic proportions worldwide. Obesity, characterized by an excessive accumulation of adipose tissue, particularly visceral fat, is a significant risk factor for the development of insulin resistance and T2D[1–3]. The dysfunction of adipose tissue plays a central role in the pathophysiology of both conditions, contributing to metabolic disturbances such as increased free fatty acids (FFAs), chronic inflammation, and altered adipokine secretion[4–7]. These changes lead to insulin resistance, impaired glucose metabolism, and the eventual progression to T2D[8–12].

At the molecular level, adipose dysfunction is marked by the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6, and resistin, which disrupt insulin signaling and impair the function of insulin-sensitive tissues, including the liver, muscle, and adipose tissue itself[7, 13]. Additionally, excess fat accumulation in non-adipose tissues, such as the liver and muscle, promotes lipid-induced toxicity and exacerbates insulin resistance. This creates a vicious cycle where metabolic disturbances in lipid and glucose metabolism perpetuate each other, contributing to the progression of both obesity and T2D[14].

Current therapeutic strategies, such as dietary interventions, exercise, oral medications, and insulin therapy, primarily focus on symptom management. However, they often fail to target the underlying causes of adipose dysfunction and glycemic dysregulation. This highlights the need for novel treatments that can address the root causes of these diseases at the molecular level. Nanotechnology presents an exciting opportunity to do just that, by offering precise, targeted approaches that can modulate lipid metabolism, reduce inflammation, and improve insulin sensitivity[15–18].

This review explores the transformative role of nanotechnology in managing adipose dysfunction and improving glycemic control in obesity and T2D. We will examine how nanotechnology-driven interventions can target adipose tissue, restore insulin sensitivity, and improve glucose metabolism, as well as the challenges and translational opportunities associated with these technologies in clinical practice.

## 2. The Role of Adipose Dysfunction in Obesity and Diabetes

Adipose tissue dysfunction is central to the development of obesity and T2D, and it involves both structural and functional changes in fat cells. In obesity, adipocytes become hypertrophic and release a range of bioactive molecules, including pro-inflammatory cytokines, chemokines, and adipokines[19–21]. These inflammatory mediators, such as TNF-α, IL-6, and resistin, contribute to insulin resistance by interfering with insulin signaling pathways in target tissues like muscle, liver, and adipose tissue itself[3].

The secretion of these inflammatory molecules leads to chronic low-grade inflammation in adipose tissue, which not only disrupts insulin action but also promotes ectopic fat deposition in non-adipose tissues such as the liver and skeletal muscle[9, 10, 22]. This ectopic fat deposition impairs the function of insulin-sensitive tissues, exacerbating insulin resistance and glucose intolerance. In the liver, excess fat accumulation leads to the development of non-alcoholic fatty liver disease (NAFLD), a condition commonly seen in individuals with obesity and T2D, which further impairs glucose homeostasis and insulin sensitivity[23–25].

Additionally, the dysregulation of adipokine secretion plays a key role in metabolic dysfunction. For example, leptin, which is typically involved in regulating energy balance, becomes dysregulated in obesity, contributing to leptin resistance and further promoting insulin resistance. The imbalance of adipokines such as adiponectin, which is typically anti-inflammatory and insulin-sensitizing, is also altered in obesity, exacerbating the pro-inflammatory environment that drives metabolic dysfunction[22, 26].

Given the central role of adipose dysfunction in the pathogenesis of obesity and T2D, strategies to target and restore normal adipose function are crucial for improving glycemic control and addressing insulin resistance. Nanotechnology-based therapies, with their ability to target specific tissues and modulate adipose-related pathways, offer a promising approach to tackling these issues at the molecular level.

## 3. Nanotechnology-Driven Drug Delivery for Modulating Adipose Dysfunction

Nanotechnology-driven drug delivery systems offer an innovative approach for targeting adipose dysfunction in obesity and T2D. Traditional drug delivery methods often fail to deliver therapeutic agents to their intended sites of action in sufficient concentrations, leading to suboptimal therapeutic outcomes[27]. Nanoparticles, with their small size, large surface area, and ability to encapsulate both hydrophilic and hydrophobic drugs, provide an ideal platform for targeted delivery to adipose tissue and other key metabolic organs[28–30].

Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles (SLNs), are commonly used to deliver therapeutic agents to adipose tissue. These nanoparticles can be functionalized with targeting ligands, such as peptides or antibodies, to enhance their specificity for adipocytes or specific receptors involved in adipose dysfunction[5, 31, 32]. For example, nanoparticles can be engineered to deliver anti-inflammatory drugs, cytokine inhibitors, or agents that restore adipokine balance, reducing the chronic inflammation that characterizes adipose dysfunction in obesity and T2D.

Polymeric nanoparticles also offer great potential for modulating adipose tissue function. These nanoparticles can be designed to release their cargo in a controlled manner, either in response to environmental cues, such as changes in pH, or biological signals, such as enzyme activity[33–35]. By targeting adipose tissue with these nanoparticles, drugs can be delivered directly to the site of inflammation, reducing systemic side effects and improving therapeutic efficacy.

Nanotechnology-driven drug delivery systems can also be used to deliver agents that promote adipogenesis (the formation of new adipocytes) or regulate adipocyte function, helping to restore the balance between white and brown adipose tissue. This can improve lipid metabolism and insulin sensitivity, offering an additional approach to managing obesity and T2D at the cellular level.

## 4. Nanotechnology in Modulating Insulin Sensitivity and Glycemic Control

The ability to modulate insulin sensitivity is a key therapeutic goal in managing obesity and type 2 diabetes (T2D). Nanotechnology provides innovative ways to improve insulin sensitivity by delivering insulin-sensitizing agents directly to insulin-resistant tissues, such as the liver, skeletal muscle, and adipose tissue[27, 36, 37]. Nanoparticles can be engineered to carry insulin-sensitizing agents, such as metformin, thiazolidinediones (TZDs), or GLP-1 agonists, which can enhance insulin signaling and improve glucose uptake in peripheral tissues.

For example, polymeric nanoparticles can be designed to deliver metformin, a commonly used oral hypoglycemic agent, directly to the liver, where it can reduce glucose production and improve insulin sensitivity[38]. Similarly, GLP-1 agonists, which promote insulin secretion and improve insulin sensitivity, can be delivered via nanocarriers to enhance their efficacy and reduce the need for frequent injections[39].

In addition to enhancing insulin sensitivity, nanocarriers can be used to modulate key enzymes involved in glucose metabolism, such as AMP-activated protein kinase (AMPK) and glucokinase[31, 40, 41]. These enzymes play critical roles in regulating glucose uptake and utilization, and their modulation can help restore normal glucose homeostasis in insulin-resistant tissues. Nanoparticles designed to deliver these enzymes or their activators can help improve glucose metabolism and reduce hyperglycemia.

By targeting insulin resistance and restoring normal insulin signaling, nanotechnology-driven therapies have the potential to improve glycemic control in individuals with obesity and T2D, offering more precise and effective treatments compared to traditional therapies.

## 5. Challenges in Translating Nanotechnology to Clinical Practice

Despite the significant promise of nanotechnology in modulating adipose dysfunction and glycemic control in obesity and T2D, several challenges remain in translating these therapies from the laboratory to clinical practice.

### Safety and Biocompatibility

The safety and biocompatibility of nanoparticles are of paramount concern, especially when they are used in long-term treatments for chronic diseases such as obesity and T2D. Nanoparticles can accumulate in vital organs, such as the liver, kidneys, and spleen, potentially leading to toxicity. Long-term toxicological studies are necessary to assess the safety profile of nanoparticles and their potential for causing adverse effects in humans[30].



### Manufacturing and Scalability

The scalability and reproducibility of nanoparticle-based therapies present significant challenges[42]. While laboratory-scale production of nanoparticles may be relatively straightforward, scaling up production to meet clinical demands requires cost-effective manufacturing methods and standardized quality control. Ensuring that nanomedicines can be manufactured consistently and at large scale is critical for their successful translation into clinical settings[42].

### Personalized Approaches

Obesity and T2D are complex diseases with considerable inter-individual variability. Factors such as genetics, disease severity, and comorbidities can influence the effectiveness of nanomedicine[43]. Personalized approaches to nanotherapy, based on patient-specific factors, will be essential for optimizing the efficacy of these treatments and ensuring that they are tailored to individual needs.

## 6. Translational Opportunities and Future Perspectives

The future of nanotechnology in the treatment of obesity and T2D is promising, with significant translational opportunities on the horizon. Advances in nanomedicine, including the development of smart nanocarriers that respond to specific biological signals, could further enhance the precision and efficacy of nanotherapies. Combining nanotechnology with other therapeutic modalities, such as gene therapy, could offer more comprehensive solutions for managing obesity and T2D at the molecular level.

Furthermore, the integration of nanotechnology with personalized medicine approaches will enable more effective treatments tailored to the unique needs of each patient. As research in nanomedicine continues to evolve, the development of nanocarriers that target multiple pathways involved in obesity and T2D, such as inflammation, lipid metabolism, and insulin resistance, will provide a holistic approach to managing these diseases.

## CONCLUSION

Nanotechnology has the potential to revolutionize the treatment of obesity and type 2 diabetes by addressing the root causes of adipose dysfunction and glycemic dysregulation. By providing targeted, precise delivery of therapeutic agents that modulate lipid metabolism, enhance insulin sensitivity, and restore glucose homeostasis, nanomedicine offers a promising approach to improving the management of these complex metabolic disorders. However, challenges related to safety, scalability, and patient variability must be addressed before these therapies can be widely adopted in clinical practice. With continued research and innovation, nanotechnology-driven interventions hold the potential to significantly improve therapeutic outcomes in obesity-related metabolic diseases and ultimately transform the way these conditions are treated.

## REFERENCES


1. Patra, D., Banerjee, D., Ramprasad, P., Roy, S., Pal, D., Dasgupta, S.: Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Front. Mol. Biosci. 10, 1224982 (2023). https://doi.org/10.3389/fmolb.2023.1224982
2. Yashi, K., Daley, S.F.: Obesity and Type 2 Diabetes. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
3. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
4. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
5. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
6. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat. Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481

7. Bou Matar, D., Zhra, M., Nassar, W.K., Altemyatt, H., Naureen, A., Abotouk, N., Elahi, M.A., Aljada, A.: Adipose tissue dysfunction disrupts metabolic homeostasis: mechanisms linking fat dysregulation to disease. Front. Endocrinol. 16, (2025). https://doi.org/10.3389/fendo.2025.1592683
8. Bansal, S.K., Bansal, M.B.: Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10–S22 (2024). https://doi.org/10.1111/apt.17930
9. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
10. Kang, H.S., Liao, G., DeGraff, L.M., Gerrish, K., Bortner, C.D., Garantziotis, S., Jetten, A.M.: CD44 Plays a Critical Role in Regulating Diet-Induced Adipose Inflammation, Hepatic Steatosis, and Insulin Resistance. PLOS ONE. 8, e58417 (2013). https://doi.org/10.1371/journal.pone.0058417
11. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
12. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
13. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
14. Jouy, S.H., Mohan, S., Scichilone, G., Mostafa, A., Mahmoud, A.M.: Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines. 12, (2024). https://doi.org/10.3390/biomedicines12092129
15. Ahmad, U., Islam, A., Khan, M.M., Akhtar, J.: Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators. Yale J. Biol. Med. 98, 227–235 (2025). https://doi.org/10.59249/GVNM8843
16. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
17. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
18. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
19. Richard, A.J., White, U., Elks, C.M., Stephens, J.M.: Adipose Tissue: Physiology to Metabolic Dysfunction. In: Feingold, K.R., Adler, R.A., Ahmed, S.F., Anawalt, B., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hamilton, E., Hofland, J., Jan de Beur, S., Kalra, S., Kaltsas, G., Kapoor, N., Kim, M., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrère, B., Levy, M., McGee, E.A., McLachlan, R., Muzumdar, R., Purnell, J., Rey, R., Sahay, R., Shah, A.S., Sperling, M.A., Stratakis, C.A., Trence, D.L., and Wilson, D.P. (eds.) Endotext. MDText.com, Inc., South Dartmouth (MA) (2000)
20. Ahmed, B., Sultana, R., Greene, M.W.: Adipose tissue and insulin resistance in obese. Biomed. Pharmacother. 137, 111315 (2021). https://doi.org/10.1016/j.biopha.2021.111315
21. Cimini, F.A., Sentinelli, F., Oldani, A., Barchetta, I., Cavallo, M.G.: Adipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms262110256
22. Choi, H.M., Doss, H.M., Kim, K.S.: Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int. J. Mol. Sci. 21, 1219 (2020). https://doi.org/10.3390/ijms21041219
23. Mann, V., Sundaresan, A., Shishodia, S.: Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis. Biology. 13, 241 (2024). https://doi.org/10.3390/biology13040241
24. Saleh, H.A., Yousef, M.H., Abdelnaser, A.: The Anti-Inflammatory Properties of Phytochemicals and Their Effects on Epigenetic Mechanisms Involved in TLR4/NF-κB-Mediated Inflammation. Front. Immunol. 12, 606069 (2021). https://doi.org/10.3389/fimmu.2021.606069
25. Wu, B., Sodji, Q.H., Oyelere, A.K.: Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers. 14, 552 (2022). https://doi.org/10.3390/cancers14030552

26. Bocian-Jastrzębska, A., Malczewska-Herman, A., Kos-Kudła, B.: Role of Leptin and Adiponectin in Carcinogenesis. Cancers. 15, 4250 (2023). https://doi.org/10.3390/cancers15174250
27. Sibuyi, N.R.S., Moabelo, K.L., Meyer, M., Onani, M.O., Dube, A., Madiehe, A.M.: Nanotechnology advances towards development of targeted-treatment for obesity. J. Nanobiotechnology. 17, 122 (2019). https://doi.org/10.1186/s12951-019-0554-3
28. Ahmar, H.: Nonenzymatic Electrochemical Detection of Glucose Using Screen-Printed Electrode Modified with Pd–Au Nanoparticles Encapsulated on Dendrimer Grafted Multi-Wall Carbon Nanotubes. Curr. Appl. Sci. 2, 67–78 (2024). https://doi.org/10.22034/cas.2022.343533.1019
29. Barua, S., Mitragotri, S.: Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today. 9, 223–243 (2014). https://doi.org/10.1016/j.nantod.2014.04.008
30. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347–380 (2019). https://doi.org/10.1007/s40005-019-00439-x
31. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
32. Mohite, P., Singh, S., Pawar, A., Sangale, A., Prajapati, B.G.: Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv. 3, (2023). https://doi.org/10.3389/fddev.2023.1232012
33. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
34. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
35. Zielińska, A., Carreiró, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., Silva, A.M., Santini, A., Souto, E.B.: Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules. 25, 3731 (2020). https://doi.org/10.3390/molecules25163731
36. Mansoori, G.-A.: The Role of Nanotechnology to Combat Major Recent Worldwide Challenges. Curr. Appl. Sci. 1, 1–8 (2023). https://doi.org/10.22034/cas.2021.144244
37. Zhang, M., Liu, E., Cui, Y., Huang, Y.: Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 14, 212–227 (2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0054
38. Zhou, S., Chen, Z., Li, X., Yue, F., Ma, L., Zhao, S., Wang, F., Luo, J.: Metformin-based internally charged nanoparticles for oral insulin delivery with injection-matched efficacy. Mater. Des. 257, 114484 (2025). https://doi.org/10.1016/j.matdes.2025.114484
39. Iqbal, N., Ambery, P., Logue, J., Mallappa, A., Sjöström, C.D.: Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism. Diabetes Res. Clin. Pract. 199, 110669 (2023). https://doi.org/10.1016/j.diabres.2023.110669
40. Bera, R., Pathak, S., Srivastava, P., Ghosh, M., Sharma, A., Ahmed, N.Z., Karwasra, R., Akram, U., Kumar, P., Sharma, B., Sharma, N.: Biomimetic nanocarriers for the therapy and management of intestinal inflammations. Int. J. Pharm. X. 10, 100377 (2025). https://doi.org/10.1016/j.ijpx.2025.100377
41. Daoud, E., Abdulsahib, W.K., Ismael, S.H., Roopashree, R., Ray, S., Nellore, J., Mukherjee, G., Chauhan, A.S., Kholiyeva, M.: Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier. Discov. Oncol. 16, 2286 (2025). https://doi.org/10.1007/s12672-025-04057-y
42. Desai, N.: Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 14, 282–295 (2012). https://doi.org/10.1208/s12248-012-9339-4
43. Wang, L., Wang, Q., Xiong, Y., Shi, W., Qi, X.: Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges. Diabetes Metab. Syndr. Obes. 18, 3427–3445 (2025). https://doi.org/10.2147/DMSO.S540103


**CITE AS: Muhindo Anitah (2026). From Adipose Dysfunction to Glycemic Control: The Transformative Role of Nanotechnology in Obesity and Diabetes. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):1-5. https://doi.org/10.59298/NIJSES/2026/72.152026**